Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P10275: Variant p.Arg609Lys

Androgen receptor
Gene: AR
Feedback?
Variant information Variant position: help 609 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Lysine (K) at position 609 (R609K, p.Arg609Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are large size and basic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In PAIS and breast cancer; defective nuclear localization. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 609 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 920 The length of the canonical sequence.
Location on the sequence: help EGKQKYLCASRNDCTIDKFR R KNCPSCRLRKCYEAGMTLGA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

                              EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

Rhesus macaque                EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

Chimpanzee                    EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

Mouse                         EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

Rat                           EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

Pig                           EGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 920 Androgen receptor
DNA binding 560 – 632 Nuclear receptor
Zinc finger 596 – 620 NR C4-type
Region 552 – 919 Interaction with LPXN
Region 572 – 662 Interaction with HIPK3
Region 592 – 919 Interaction with CCAR1



Literature citations
Point mutations detected in the androgen receptor gene of three men with partial androgen insensitivity syndrome.
Saunders P.T.; Padayachi T.; Tincello D.G.; Shalet S.M.; Wu F.C.;
Clin. Endocrinol. (Oxf.) 37:214-220(1992)
Cited for: VARIANTS PAIS LYS-609 AND LEU-867; Androgen receptor gene mutation in male breast cancer.
Lobaccaro J.-M.; Lumbroso S.; Belon C.; Galtier-Dereure F.; Bringer J.; Lesimple T.; Namer M.; Cutuli B.F.; Pujol H.; Sultan C.;
Hum. Mol. Genet. 2:1799-1802(1993)
Cited for: VARIANT PAIS/BREAST CANCER LYS-609; Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome.
Tincello D.G.; Saunders P.T.; Hodgins M.B.; Simpson N.B.; Edwards C.R.; Hargreaves T.B.; Wu F.C.;
Clin. Endocrinol. (Oxf.) 46:497-506(1997)
Cited for: VARIANTS PAIS LYS-609 AND GLY-773;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.